First Tracks Biotherapeutics Stock (NASDAQ:TRAX)


FinancialsChart

Previous Close

$44.03

52W Range

$14.72 - $49.91

50D Avg

$30.35

200D Avg

$25.38

Market Cap

$1.54B

Avg Vol (3M)

$742.18K

Beta

3.37

Div Yield

-

TRAX Company Profile


First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

104

IPO Date

Apr 20, 2026

Website

TRAX Performance


TRAX Financial Summary


Dec 25Dec 24Dec 23
Revenue---
Operating Income$-179.01M$-181.10M$-118.46M
Net Income$-166.09M$-163.71M$-106.15M
EBITDA$-178.45M$-178.70M$-116.08M
Basic EPS--$-3.05
Diluted EPS--$-3.05

Fiscal year ends in Dec 25 | Currency in USD